Athenex, Inc. (Nasdaq: ATNX), a global biopharmaceutical company
dedicated to the discovery, development and commercialization of
novel therapies for the treatment of cancer and related conditions,
today announced the appointment of Daniel Lang, MD, as President of
Axis Therapeutics Limited and Senior Director of Corporate
Development at Athenex, Inc.
Dr. Lang joins Axis and Athenex to lead the operations of the
company’s T-cell receptor-engineered T cells (TCR-T) immunotherapy
platform for oncology and to assist with corporate development
strategy for Athenex. In this new role, Dr. Lang will report to Dr.
Johnson Lau, Chief Executive Officer of Athenex and Axis, and will
work closely with the management teams of both companies.
Dr. Lang has more than 25 years of experience as a physician,
scientist and investor. Most recently, he was the Chief
Investment Officer of RS Value, an investment franchise of Victory
Capital, overseeing the RS Value strategies, as well as an analyst
and portfolio manager for healthcare investments since 2009.
Prior to RS Value, Dr. Lang was an analyst at Farallon Capital
Management, a global multi-strategy hedge fund, responsible for
healthcare investments. Dr. Lang started his career as a
physician scientist, completing a cardiology fellowship at the
University of California, San Francisco. He earned his B.A.
in Chemistry from Cornell University and M.D. from Weill Cornell
Medical College.
“We are delighted to have Daniel join us at this important
time,” stated Dr. Johnson Lau, Chairman and CEO of Athenex and CEO
of Axis. “With his experience as an executive and successful
investor, we look forward to the leadership and insight he will
bring to Athenex and Axis as we continue to execute on our mission
to deliver innovative products that will improve patient outcomes
in oncology.”
Dr. Lang commented, “Athenex is a leading biotechnology company
with positive Phase III results from two pivotal programs for oral
paclitaxel and encequidar and for tirbanibulin ointment. The
company is in a unique and enviable position of developing a rich
pipeline of products spanning small molecules, biologics, and cell
therapies that have the potential to transform oncology
treatment. I am thrilled to join an organization with an
innovative culture and a clear mission to improve patients’
lives.”
In July 2018, Athenex and Xiangxue Life Sciences (“XLifeSc”)
entered into an agreement to establish a new joint venture named
Axis Therapeutics Limited, which owns the global (excluding
mainland China) rights to the T-cell receptor Affinity Enhanced
Specific T-cell (TAEST) technology. XLifeSc retains the mainland
China rights. Axis Therapeutics is leading the research,
development and commercialization efforts of T-cell
receptor-engineered T cells, a form of cancer immunotherapy, in the
licensed territories.
About Athenex, Inc. Founded in
2003, Athenex, Inc. is a global clinical stage
biopharmaceutical company dedicated to becoming a leader in the
discovery, development and commercialization of next generation
drugs for the treatment of cancer. Athenex is organized
around three platforms, including an Oncology Innovation Platform,
a Commercial Platform and a Global Supply Chain Platform. The
Company’s current clinical pipeline is derived from four different
platform technologies: (1) Orascovery, based on non-absorbed
P-glycoprotein inhibitor, (2) Src kinase inhibition, (3) T-cell
receptor-engineered T-cells (TCR-T), and (4) Arginine deprivation
therapy. Athenex’s employees worldwide are dedicated to improving
the lives of cancer patients by creating more active and tolerable
treatments. Athenex has offices
in Buffalo and Clarence, New York; Cranford,
New Jersey; Houston, Texas; Chicago, Illinois; Hong
Kong; Taipei, Taiwan; multiple locations
in Chongqing, China; and Manchester, UK. For more
information, please visit www.athenex.com.
Forward-Looking Statements Except for
historical information, all of the statements, expectations, and
assumptions contained in this press release are forward-looking
statements. These forward-looking statements are typically
identified by terms such as “anticipate,” “believe,” “continue,”
“could,” “estimate,” “evaluate,” “expect,” “foresee,” “guidance,”
“intend,” “investigate,” “likely,” “may,” “plan,” “potential,”
“predict,” “preliminary,” “prepare,” “potential,” “probable,”
“project,” “promising,” “seek,” “should,” “will,” “would,” and
similar expressions. Actual results might differ materially
from those explicit or implicit in the forward-looking statements.
Important factors that could cause actual results to differ
materially include: the development stage of our primary clinical
candidates and related risks involved in drug development, clinical
trials, regulation, manufacturing and commercialization; our
reliance on third parties for success in certain areas of
Athenex’s business; our history of operating losses and need to
raise additional capital to continue as a going concern;
competition; intellectual property risks; risks relating to doing
business in China; the uncertainty of when, if at all, we will
be able to resume producing API in our Chongqing plant;
and the other risk factors set forth from time to time in
our SEC filings, copies of which are available for free
in the Investor Relations section of our website
at http://ir.athenex.com/phoenix.zhtml?c=254495&p=irol-sec or
upon request from our Investor Relations Department. All
information provided in this release is as of the date hereof and
we assume no obligation and do not intend to update these
forward-looking statements, except as required by law.
CONTACTS Investor Relations: Tim McCarthy
Managing Director, LifeSci Advisors, LLC Tel: +1
716-427-2952 Direct: +1 212-915-2564
Athenex, Inc.: Randoll Sze Chief Financial Officer
Email: randollsze@athenex.com
Jacqueline Li Corporate Development and Investor Relations
Email: jacquelineli@athenex.com
Athenex (NASDAQ:ATNX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Athenex (NASDAQ:ATNX)
Historical Stock Chart
From Apr 2023 to Apr 2024